Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Liabilities and Shareholders Equity (2023 - 2025)

Ascentage Pharma Group International posted quarterly Liabilities and Shareholders Equity of $558.8 million for Q4 2025, up 53.34% year-on-year from $364.4 million in Q4 2024, and up 32.7% on a QoQ basis from $421.1 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $558.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 53.34% year-over-year to $558.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 billion (changed N/A YoY), and the FY2025 full-year result was $551.5 million, up 51.34% from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 stood at $558.8 million, up from $421.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $558.8 million in Q4 2025 and bottomed at $347.3 million in Q4 2023.
  • The 3-year median for Liabilities and Shareholders Equity is $392.8 million (2024), against an average of $422.9 million.
  • The widest annual swing landed in 2024, when Liabilities and Shareholders Equity rose 4.94%; it then soared 53.34% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $347.3 million in 2023, then climbed by 4.94% to $364.4 million in 2024, then jumped by 53.34% to $558.8 million in 2025.
  • The last three Liabilities and Shareholders Equity figures came in at $558.8 million (Q4 2025), $421.1 million (Q2 2025), and $364.4 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 14.93 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 37.37 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 78.88 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 26.48 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 40.87 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - 23.64 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 5.13 Bn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 558.84 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 558.84 Mn
Jun 30, 2025 421.14 Mn
Dec 31, 2024 364.44 Mn
Dec 31, 2023 347.27 Mn